The Complete Peptide Glossary: 200+ Terms Every Researcher Should Know

The Complete Peptide Glossary: Your Definitive Reference Guide

Peptide science spans organic chemistry, pharmacology, molecular biology, analytical chemistry, and clinical research — each discipline contributing its own specialized vocabulary. For researchers entering the field or experienced scientists encountering unfamiliar terminology, having a comprehensive peptide glossary is essential for understanding the literature, interpreting certificates of analysis, and designing rigorous research protocols.

This definitive glossary defines over 200 terms organized alphabetically within thematic categories, with each definition contextualized for peptide research applications. Cross-references to our in-depth research articles and product catalog are provided throughout. Bookmark this page as your go-to reference — and visit our research hub for detailed guides on every topic mentioned here.

Basic Peptide Chemistry

Acetylation

The addition of an acetyl group (CH3CO-) to a molecule, most commonly to the N-terminus of a peptide. N-terminal acetylation protects the peptide from aminopeptidase degradation, extending its biological half-life. It also neutralizes the positive charge at the N-terminus, which can affect receptor binding and membrane permeability. Many research peptides including N-Acetyl Semax Amidate use acetylation as a stability-enhancing modification. See our peptide stability and degradation guide.

Acylation

The attachment of a fatty acid chain to a peptide, typically via a lysine side chain or the N-terminus. Acylation increases lipophilicity and promotes binding to serum albumin, dramatically extending circulating half-life. This modification is used in long-acting GLP-1 receptor agonists like semaglutide (C18 fatty diacid) and liraglutide (C16 fatty acid). See lipidation peptide modification.

Amidation

The conversion of the C-terminal carboxyl group (-COOH) to an amide (-CONH2). C-terminal amidation mimics the natural post-translational modification found in many bioactive peptides, protects against carboxypeptidase degradation, and can enhance receptor binding affinity. Approximately 50% of all known bioactive peptides are naturally amidated. The modification neutralizes the negative charge at the C-terminus.

Amino Acid

The fundamental building block of peptides and proteins. Each amino acid contains an amino group (-NH2), a carboxyl group (-COOH), a hydrogen atom, and a variable side chain (R group) attached to a central alpha-carbon. There are 20 standard (proteinogenic) amino acids encoded by the genetic code, plus numerous non-standard amino acids used in synthetic peptide chemistry. Amino acids are classified by their side chain properties: nonpolar/hydrophobic (Ala, Val, Leu, Ile, Pro, Phe, Trp, Met), polar/uncharged (Ser, Thr, Cys, Tyr, Asn, Gln), positively charged (Lys, Arg, His), and negatively charged (Asp, Glu).

Backbone

The repeating chain of N-Cα-C(O) atoms that forms the structural core of a peptide, from which the amino acid side chains extend. The backbone adopts specific conformations (secondary structures) stabilized by hydrogen bonds between backbone amide NH and carbonyl C=O groups. Backbone modifications such as N-methylation or incorporation of beta-amino acids can enhance metabolic stability and oral bioavailability.

Beta-Amino Acid

An amino acid with an extra methylene group in the backbone (the amino group is on the beta-carbon rather than the alpha-carbon). Incorporation of beta-amino acids into peptides creates “beta-peptides” or “alpha/beta-peptides” that are resistant to proteolytic degradation while retaining biological activity. This is an important strategy in peptide structure-activity relationship research.

C-Terminus

The end of a peptide chain bearing a free carboxyl group (-COOH). By convention, peptide sequences are written from N-terminus (left) to C-terminus (right). The C-terminus is a target for carboxypeptidase enzymes and is commonly modified by amidation to enhance stability and bioactivity.

Cleavage

In solid-phase peptide synthesis (SPPS), cleavage refers to the chemical release of the completed peptide from the solid resin support. This is typically accomplished using strong acid (95% TFA for Fmoc chemistry, liquid HF for Boc chemistry). The cleavage step simultaneously removes most side-chain protecting groups, yielding the crude, deprotected peptide. See peptide synthesis methods explained.

Conjugation

The covalent attachment of a peptide to another molecule such as a polymer (PEGylation), fatty acid (lipidation), carbohydrate (glycosylation), fluorescent dye (labeling), or another peptide. Conjugation is used to modify pharmacokinetic properties, add targeting functionality, or enable detection and tracking.

Cyclization

The formation of a ring structure within a peptide, creating a cyclic peptide. Cyclization can occur through head-to-tail (N-to-C terminus), side-chain-to-side-chain, side-chain-to-backbone, or disulfide bond linkages. Cyclic peptides generally exhibit enhanced metabolic stability, improved receptor selectivity, and sometimes oral bioavailability compared to their linear counterparts. See cyclization and peptide stability.

D-Amino Acid

The mirror image (enantiomer) of the naturally occurring L-amino acid. D-amino acids are not recognized by most proteolytic enzymes, so their incorporation into peptides at strategic positions dramatically increases resistance to enzymatic degradation. D-amino acid substitution is a common strategy for improving peptide metabolic stability while often maintaining biological activity.

Deprotection

The removal of chemical protecting groups from amino acid side chains and/or the peptide backbone during or after solid-phase synthesis. In Fmoc chemistry, the Fmoc group is removed with piperidine (20% in DMF) at each coupling cycle, while side-chain protecting groups are removed during final TFA cleavage. Incomplete deprotection leads to deletion sequences and reduced purity.

Dipeptide

A peptide consisting of exactly two amino acids joined by a single peptide bond. Examples include carnosine (beta-alanyl-L-histidine) and the sweetener aspartame. Despite their small size, some dipeptides exhibit significant biological activity.

Disulfide Bond

A covalent bond formed between the sulfur atoms of two cysteine residues (-S-S-). Disulfide bonds stabilize peptide and protein three-dimensional structure and are critical for the biological activity of many peptides including oxytocin, vasopressin, and insulin. Proper disulfide bond formation during synthesis requires careful oxidation conditions. See disulfide bonds and peptide folding.

Fmoc (Fluorenylmethyloxycarbonyl)

The most widely used N-alpha protecting group in modern solid-phase peptide synthesis. Fmoc is base-labile (removed by piperidine) and acid-stable, allowing orthogonal protection strategies where side-chain protecting groups (acid-labile) remain intact during backbone deprotection cycles. Fmoc-SPPS is the standard method used by most peptide manufacturers. See peptide synthesis methods.

Isoelectric Point (pI)

The pH at which a peptide carries no net electrical charge. At pH values below the pI, the peptide carries a net positive charge; above the pI, a net negative charge. The pI influences peptide solubility (minimum solubility typically occurs at the pI), chromatographic behavior, and formulation strategies.

Lyophilization (Freeze-Drying)

The process of removing water from a frozen peptide solution by sublimation under vacuum, producing a dry, stable powder. Lyophilized peptides have dramatically extended shelf life compared to solutions because the absence of water prevents hydrolysis and reduces aggregation. Most research peptides are supplied in lyophilized form. See lyophilized peptide handling guide and peptide stability guide.

N-Terminus

The end of a peptide chain bearing a free amino group (-NH2). The first amino acid in a peptide sequence (written on the left) is the N-terminal residue. The N-terminus is a target for aminopeptidase enzymes and is commonly modified by acetylation or other capping strategies to enhance stability.

Oligopeptide

A short peptide typically containing 2–20 amino acid residues. The term distinguishes shorter sequences from polypeptides (20–50+ residues) and proteins (typically 50+ residues with defined three-dimensional structure). Most research peptides fall into the oligopeptide category.

PEGylation

The covalent attachment of polyethylene glycol (PEG) polymer chains to a peptide. PEGylation increases the hydrodynamic radius, reducing renal clearance and extending circulating half-life. It also shields the peptide from proteolytic degradation and reduces immunogenicity. The trade-off is typically reduced receptor binding affinity per molecule, which is compensated by increased exposure time. See PEGylation peptide modification.

Peptide Bond

The covalent amide bond (-CO-NH-) formed between the carboxyl group of one amino acid and the amino group of another, with the loss of a water molecule (condensation reaction). The peptide bond has partial double-bond character due to resonance, making it planar and restricting rotation. This planarity is fundamental to peptide secondary structure. Peptide bonds are cleaved by proteases (peptidases) and by acid/base hydrolysis.

Polypeptide

A chain of amino acids typically containing more than 20 residues linked by peptide bonds. The distinction between a polypeptide and a protein is somewhat arbitrary, but proteins generally have defined three-dimensional structures and biological functions, while polypeptide is a chemical descriptor.

Post-Translational Modification (PTM)

Chemical modifications to a peptide or protein that occur after ribosomal translation. PTMs include phosphorylation, glycosylation, acetylation, methylation, ubiquitination, and many others. These modifications regulate protein function, localization, and stability. Many synthetic peptide modifications (acetylation, amidation) mimic naturally occurring PTMs.

Primary Structure

The linear sequence of amino acids in a peptide, reading from N-terminus to C-terminus. Primary structure is the most fundamental level of peptide structure and directly determines all higher-order structural features. It is conventionally written using either three-letter codes (Ala-Gly-Ser) or one-letter codes (AGS).

Quaternary Structure

The arrangement of multiple polypeptide chains (subunits) into a functional complex. While most research peptides are too small to exhibit quaternary structure, some larger peptides and proteins (e.g., insulin, composed of A and B chains) have essential quaternary interactions.

Racemization

The conversion of an L-amino acid to its D-enantiomer (or vice versa) during peptide synthesis or storage. Racemization is an undesirable side reaction that reduces peptide purity and can alter biological activity. It is particularly problematic during activation of C-terminal residues in fragment condensation and during prolonged storage in solution. See peptide degradation and potency guide.

Secondary Structure

Regular, repeating local structural patterns in a peptide backbone stabilized by hydrogen bonds. The two most common secondary structures are the alpha-helix (a right-handed coil with 3.6 residues per turn) and the beta-sheet (extended strands connected by hydrogen bonds). Secondary structure is critical for receptor binding and biological activity in many peptides.

Solid-Phase Peptide Synthesis (SPPS)

The standard method for chemical peptide synthesis, developed by Bruce Merrifield (Nobel Prize, 1984). In SPPS, the first amino acid is anchored to an insoluble resin bead, and subsequent amino acids are added one at a time through repeated cycles of deprotection and coupling. The growing peptide remains attached to the resin throughout synthesis, allowing excess reagents and byproducts to be washed away. After assembly, the peptide is cleaved from the resin. See peptide synthesis methods explained.

Stapled Peptide

A peptide containing a synthetic hydrocarbon bridge (“staple”) that locks the peptide into an alpha-helical conformation. Stapling dramatically enhances metabolic stability, cell permeability, and binding affinity compared to unmodified helical peptides. This technology is being applied to develop peptide therapeutics that can access intracellular targets. See stapled peptides in drug design.

t-Boc (tert-Butyloxycarbonyl)

An N-alpha protecting group used in the original solid-phase peptide synthesis methodology. Boc is acid-labile (removed by TFA) and requires HF for final cleavage from the resin. Boc chemistry has been largely supplanted by Fmoc chemistry for routine synthesis but remains preferred for certain specialized applications, particularly for peptides containing acid-sensitive modifications or for very long sequences.

Tertiary Structure

The overall three-dimensional shape of a single peptide chain, determined by interactions between amino acid side chains including hydrophobic interactions, hydrogen bonds, ionic interactions, and disulfide bonds. Tertiary structure is typically relevant for larger peptides (20+ residues) and proteins.

Pharmacology Terms

Agonist

A molecule that binds to a receptor and activates it, producing a biological response. Full agonists produce the maximum possible response from the receptor; partial agonists produce a submaximal response even at full receptor occupancy. Many research peptides function as receptor agonists — for example, semaglutide is a GLP-1 receptor agonist, and ipamorelin is a GHS-R1a agonist.

Allosteric Modulator

A molecule that binds to a receptor at a site distinct from the orthosteric (primary) binding site and modifies the receptor’s response to its endogenous ligand. Positive allosteric modulators (PAMs) enhance receptor activation; negative allosteric modulators (NAMs) reduce it. Allosteric modulation offers the advantage of preserving physiological signaling patterns. See allosteric modulation of peptide receptors.

Antagonist

A molecule that binds to a receptor without activating it, blocking the binding and action of agonists. Competitive antagonists compete with agonists for the orthosteric binding site and can be overcome by increasing agonist concentration. Non-competitive antagonists bind irreversibly or at allosteric sites and cannot be overcome by increasing agonist concentration.

AUC (Area Under the Curve)

A pharmacokinetic parameter representing the total drug exposure over time, calculated as the integral of the plasma concentration-time curve. AUC reflects both the extent of absorption and the rate of elimination. A higher AUC indicates greater total systemic exposure to the peptide. AUC is a critical parameter for comparing peptide bioavailability across delivery routes.

Biased Agonism (Functional Selectivity)

The ability of different agonists at the same receptor to preferentially activate different downstream signaling pathways. For example, a biased GLP-1R agonist might preferentially activate G-protein signaling (beneficial metabolic effects) over beta-arrestin recruitment (associated with nausea). Biased agonism is an active area of peptide drug design. See GPCR peptide receptor pharmacology.

Bioavailability

The fraction of an administered dose of a peptide that reaches the systemic circulation in its active form. Intravenous administration has 100% bioavailability by definition. Subcutaneous bioavailability for peptides is typically 50–90%. Oral bioavailability for most peptides is less than 1–2% due to gastrointestinal degradation and poor absorption, though notable exceptions include oral BPC-157. See peptide bioavailability enhancement and oral vs. injectable BPC-157.

Clearance

The volume of plasma from which a drug is completely removed per unit time (typically expressed as mL/min or L/hr). Peptides are cleared primarily through renal filtration (for small peptides), hepatic metabolism, and receptor-mediated endocytosis. Modifications that increase peptide size (PEGylation) or promote albumin binding (acylation) reduce clearance and extend half-life.

Cmax

The maximum (peak) plasma concentration of a drug achieved after administration. Cmax, along with Tmax, characterizes the absorption phase of pharmacokinetics. For peptides with narrow therapeutic windows, excessive Cmax can cause side effects, leading to the development of sustained-release formulations.

Desensitization

A reduction in receptor responsiveness following prolonged or repeated agonist exposure. Desensitization can occur through receptor phosphorylation (homologous desensitization), receptor internalization, or downstream signaling pathway modulation. Peptide cycling protocols are designed partly to prevent or reverse desensitization. See peptide cycling protocols guide.

Dose-Response Curve

A graphical representation of the relationship between drug dose (or concentration) and the magnitude of the biological response. Dose-response curves are typically sigmoidal when plotted on a log scale. Key parameters derived from the curve include EC50 (potency), Emax (efficacy), Hill coefficient (cooperativity), and therapeutic window. See peptide dose titration protocol.

Downregulation

A decrease in the number of receptors on a cell surface, typically in response to prolonged agonist stimulation. Downregulation reduces cellular sensitivity to the agonist and is a mechanism of tolerance. It involves receptor internalization followed by lysosomal degradation rather than recycling. This is distinct from desensitization, which involves functional inactivation of existing receptors.

EC50 (Effective Concentration 50%)

The concentration of a drug that produces 50% of its maximum possible effect. EC50 is the standard measure of drug potency: a lower EC50 indicates a more potent compound. For peptides, EC50 values typically range from picomolar (e.g., Dihexa) to micromolar concentrations depending on the peptide and its target.

First-Pass Metabolism

The metabolism of an orally administered drug by the gut wall and liver before it reaches the systemic circulation. First-pass metabolism is the primary reason for the poor oral bioavailability of most peptides: gastric acid, pepsin, pancreatic proteases, and hepatic enzymes extensively degrade peptide bonds. Strategies to overcome first-pass effects include permeation enhancers, protease inhibitors, and enteric coatings.

Half-Life (t1/2)

The time required for the plasma concentration of a drug to decrease by 50%. Most unmodified peptides have very short half-lives (minutes) due to rapid proteolytic degradation and renal clearance. Modifications such as PEGylation, acylation, and cyclization can extend peptide half-lives from minutes to days or even weeks. A drug reaches steady state after approximately 4–5 half-lives of repeated dosing.

IC50 (Inhibitory Concentration 50%)

The concentration of an inhibitor that reduces a specific biological activity by 50%. Used to quantify the potency of antagonists, enzyme inhibitors, and other inhibitory compounds. The IC50 value depends on experimental conditions including agonist concentration, unlike the Ki value which is a true thermodynamic constant.

Inverse Agonist

A molecule that binds to a receptor and produces a response opposite to that of the agonist. Unlike an antagonist, which simply blocks agonist action without producing its own effect, an inverse agonist suppresses constitutive (baseline) receptor activity. This distinction is significant for receptors with substantial constitutive activity.

Kd (Dissociation Constant)

The equilibrium dissociation constant for the binding of a ligand to its receptor, representing the concentration of ligand at which 50% of receptors are occupied. Kd is a measure of binding affinity: a lower Kd indicates stronger binding. Kd is determined independently of functional effects and is a true thermodynamic parameter, unlike EC50 or IC50.

Ki (Inhibition Constant)

The equilibrium dissociation constant for the binding of an inhibitor to its target, derived from IC50 data using the Cheng-Prusoff equation. Ki is a thermodynamic constant independent of experimental conditions (unlike IC50) and represents the true binding affinity of an inhibitor for its target.

Partial Agonist

A ligand that binds to a receptor and activates it, but produces a submaximal response even at full receptor occupancy. Partial agonists act as functional antagonists in the presence of a full agonist (competing for receptor binding but producing a weaker response) and as agonists in the absence of the full agonist.

Pharmacodynamics (PD)

The study of the biochemical and physiological effects of drugs on the body — what the drug does to the body. PD encompasses receptor binding, signal transduction, dose-response relationships, and the time course of drug effects. For peptides, PD studies examine receptor activation, downstream signaling, and functional outcomes.

Pharmacokinetics (PK)

The study of how the body absorbs, distributes, metabolizes, and eliminates drugs — what the body does to the drug. PK parameters include bioavailability, Cmax, Tmax, AUC, half-life, volume of distribution, and clearance. Peptide PK is dominated by rapid proteolytic metabolism and renal clearance of small fragments.

Steady State

The condition achieved during repeated dosing when the rate of drug administration equals the rate of drug elimination, resulting in a stable average plasma concentration. Steady state is reached after approximately 4–5 half-lives of the drug. For GH secretagogues and other peptides used in regular protocols, steady-state pharmacokinetics determine the effective exposure level.

Tachyphylaxis

A rapid and pronounced decrease in drug response following repeated administration, often occurring within minutes to hours. Tachyphylaxis is distinguished from tolerance (which develops over days to weeks) by its speed of onset. Some GH secretagogues can exhibit tachyphylaxis with too-frequent dosing, which is why pulsatile administration patterns are recommended.

Therapeutic Index (TI)

The ratio of the toxic dose to the therapeutic dose (TD50/ED50), representing the margin of safety for a drug. A higher therapeutic index indicates a wider safety margin. Most peptides have relatively high therapeutic indices compared to small-molecule drugs because their high receptor specificity limits off-target effects.

Tmax

The time after drug administration at which the maximum plasma concentration (Cmax) is achieved. For subcutaneous peptide injections, Tmax is typically 15–60 minutes. For intranasal delivery, Tmax is often 5–15 minutes for brain concentrations.

Upregulation

An increase in the number of receptors on a cell surface, typically in response to reduced agonist stimulation or antagonist exposure. Upregulation increases cellular sensitivity to the agonist. Understanding upregulation is important for peptide cycling strategies: rest periods may allow receptor upregulation, restoring sensitivity for subsequent cycles.

Volume of Distribution (Vd)

A theoretical pharmacokinetic parameter representing the apparent volume into which a drug distributes in the body. A large Vd indicates extensive tissue distribution; a small Vd indicates confinement to the plasma compartment. Most peptides have relatively small Vd due to their hydrophilicity and size, though lipidated peptides can have larger Vd.

Receptor Biology

Beta-Arrestin

An intracellular scaffolding protein recruited to activated GPCRs following receptor phosphorylation by G-protein-coupled receptor kinases (GRKs). Beta-arrestin binding terminates G-protein signaling (desensitization), initiates receptor internalization (endocytosis), and activates its own signaling cascades (MAPK, Akt). The balance between G-protein and beta-arrestin signaling is central to the concept of biased agonism in peptide pharmacology.

GHS-R1a (Growth Hormone Secretagogue Receptor 1a)

A GPCR primarily expressed in the anterior pituitary and hypothalamus that, when activated, stimulates growth hormone release. GHS-R1a is the target of ghrelin (the endogenous ligand) and synthetic GH secretagogues including ipamorelin, GHRP-2, GHRP-6, and hexarelin. GHS-R1a also regulates appetite, energy metabolism, and reward circuitry. See GHS receptor research.

GHRH-R (Growth Hormone-Releasing Hormone Receptor)

A GPCR expressed on anterior pituitary somatotroph cells that mediates the GH-releasing effects of GHRH and its analogs including CJC-1295, tesamorelin, and sermorelin. GHRH-R activation stimulates both GH synthesis and secretion through cAMP/PKA signaling. See CJC-1295 research guide.

GLP-1R (Glucagon-Like Peptide-1 Receptor)

A GPCR expressed on pancreatic beta cells, neurons, and other tissues that mediates the incretin effect and satiety signaling. GLP-1R is the target of semaglutide, tirzepatide (dual GLP-1R/GIPR agonist), and retatrutide (triple agonist). GLP-1R activation enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. See semaglutide GLP-1 research.

GPCR (G-Protein-Coupled Receptor)

The largest family of cell surface receptors, characterized by seven transmembrane alpha-helical domains. GPCRs transduce extracellular signals (peptide hormones, neurotransmitters) into intracellular responses through activation of heterotrimeric G-proteins (Gs, Gi, Gq). Approximately 50% of all drugs target GPCRs. Many research peptides act at GPCRs including GLP-1R, GHS-R1a, GHRH-R, melanocortin receptors, and opioid receptors. See GPCR peptide receptor pharmacology.

MC1R–MC5R (Melanocortin Receptors 1–5)

A family of five GPCRs that respond to melanocortin peptides (alpha-MSH, ACTH). MC1R mediates skin pigmentation and is the target of Melanotan II. MC2R is the ACTH receptor in the adrenal cortex. MC3R and MC4R regulate appetite and energy homeostasis. MC5R is involved in exocrine gland function. PT-141 (bremelanotide) primarily acts at MC3R and MC4R. See melanocortin receptor system research.

Receptor Internalization

The process by which activated cell surface receptors are engulfed into intracellular vesicles (endosomes) through clathrin-mediated or caveolae-mediated endocytosis. Internalization removes receptors from the cell surface, reducing cellular responsiveness. Internalized receptors may be recycled back to the surface (resensitization) or directed to lysosomes for degradation (downregulation).

Receptor Recycling

The process by which internalized receptors are dephosphorylated in endosomes and returned to the cell surface in a functional state, restoring cellular sensitivity. The rate of receptor recycling varies among receptor subtypes and influences the kinetics of desensitization and resensitization. Fast-recycling receptors recover sensitivity more quickly than slow-recycling receptors.

Signal Transduction

The process by which a cell converts an extracellular signal (e.g., peptide binding to a receptor) into an intracellular response through a cascade of molecular events. Common signal transduction pathways activated by peptide receptors include cAMP/PKA, PI3K/Akt, MAPK/ERK, JAK/STAT, and PLC/PKC pathways.

TrkB Receptor

A receptor tyrosine kinase that is the primary high-affinity receptor for brain-derived neurotrophic factor (BDNF). TrkB activation triggers PI3K/Akt (survival), MAPK/ERK (differentiation), and PLC-gamma (synaptic plasticity) signaling cascades. TrkB is a key mediator of the cognitive effects of peptides like Semax that upregulate BDNF. See neuropeptide signaling in the brain.

Research Methodology

Bioassay

An experimental procedure that measures the biological activity of a substance using a living system (cells, tissues, or organisms). For peptides, bioassays determine functional potency — the ability of the peptide to produce a biological response — which complements chemical purity data from HPLC and mass spectrometry. Bioassays are the gold standard for confirming that a peptide is not only pure but also biologically active.

Clinical Trial Phases

The sequential stages of human drug testing: Phase I tests safety, tolerability, and PK in a small number of healthy volunteers. Phase II evaluates efficacy and dose-response in patients with the target condition. Phase III confirms efficacy and monitors adverse effects in large patient populations. Phase IV (post-marketing surveillance) monitors long-term safety after FDA approval. See peptide clinical trial phases explained.

COA (Certificate of Analysis)

A document provided by a peptide manufacturer that reports the results of quality control testing for a specific production batch. A comprehensive COA should include identity confirmation (mass spectrometry), purity (HPLC), amino acid analysis, peptide content, water content, endotoxin levels, sterility testing, and appearance. The COA is the primary tool for evaluating peptide quality. See how to read a peptide COA.

Endotoxin

Lipopolysaccharide (LPS) components of gram-negative bacterial cell walls that can contaminate peptide preparations and cause fever, inflammation, and potentially fatal septic shock if injected. Endotoxin testing (LAL test) is a critical quality control step for injectable peptide products. USP limits for injectable products are typically less than 5 EU/kg body weight.

ESI-MS (Electrospray Ionization Mass Spectrometry)

A mass spectrometry technique that ionizes peptides by spraying a solution through a charged capillary, producing multiply charged ions suitable for mass analysis. ESI-MS is the standard method for confirming peptide identity by measuring molecular weight. It is commonly coupled with liquid chromatography (LC-ESI-MS) for simultaneous separation and identification. See mass spectrometry for peptide identification.

GMP (Good Manufacturing Practice)

A set of regulatory guidelines established by the FDA (and equivalent international agencies) that ensure pharmaceutical products are consistently produced and controlled to quality standards. GMP manufacturing involves validated processes, qualified equipment, trained personnel, and comprehensive documentation. GMP-grade peptides are required for human clinical use but are significantly more expensive than research-grade. See peptide quality control standards.

HPLC (High-Performance Liquid Chromatography)

The primary analytical technique for assessing peptide purity. In HPLC, a peptide sample is dissolved and pumped through a column packed with a stationary phase (typically C18 reversed-phase). Different components elute at different times based on their hydrophobicity, producing a chromatogram. Purity is calculated as the percentage of the target peptide peak area relative to total peak area. Research-grade peptides typically have HPLC purity of 95–99%. See peptide HPLC purity analysis.

In Vitro

Latin for “in glass” — experiments performed outside a living organism, typically in cell cultures, tissue preparations, or biochemical assays. In vitro studies allow precise control of experimental conditions and are essential for elucidating molecular mechanisms. However, they may not fully predict in vivo effects due to the absence of pharmacokinetic factors, immune responses, and multi-organ interactions.

In Vivo

Latin for “in the living” — experiments performed in a living organism, typically animal models. In vivo studies incorporate the full complexity of whole-organism biology including absorption, distribution, metabolism, elimination, and inter-organ communication. They are essential for evaluating efficacy and safety before human testing but are more expensive, time-consuming, and ethically complex than in vitro studies.

LAL Test (Limulus Amebocyte Lysate Test)

The standard assay for detecting and quantifying bacterial endotoxin in pharmaceutical products, including injectable peptides. The LAL test uses a lysate from the blood cells of the horseshoe crab (Limulus polyphemus), which forms a gel in the presence of endotoxins. Results are reported in Endotoxin Units (EU) per volume or per mass. Recombinant Factor C (rFC) assays are increasingly used as animal-free alternatives.

MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight)

A mass spectrometry technique where peptide samples are embedded in a UV-absorbing matrix, ionized by a laser pulse, and analyzed by measuring the time it takes for ions to travel through a flight tube to the detector. MALDI-TOF provides rapid, accurate molecular weight determination and is particularly useful for screening multiple peptide samples simultaneously. See mass spectrometry for peptide identification.

Net Peptide Content (NPC)

The actual percentage of active peptide in a lyophilized powder, accounting for water, salt (counterions like acetate or TFA), and minor impurities. A vial labeled “5 mg” with 70% NPC contains only 3.5 mg of actual peptide. NPC is critical for accurate dosing calculations and is reported on the COA. Typical NPC values range from 60–90% depending on the peptide and counterion.

Preclinical

The stage of drug development occurring before human clinical trials, encompassing in vitro studies, animal efficacy testing, pharmacokinetic profiling, and toxicology studies. Most research peptides discussed in the peptide research community are at the preclinical stage or earlier, with notable exceptions including semaglutide and tirzepatide which are FDA-approved drugs.

USP (United States Pharmacopeia)

An independent, scientific organization that establishes standards for the identity, strength, quality, and purity of medicines, dietary supplements, and food ingredients. USP standards are legally enforceable for products marketed in the United States. Bacteriostatic water used for peptide reconstitution should meet USP standards. See peptide quality control standards.

Peptide Categories

Antimicrobial Peptide (AMP)

A class of peptides, typically 12–50 amino acids with a net positive charge and amphipathic structure, that kill or inhibit the growth of bacteria, fungi, and/or viruses. AMPs are part of the innate immune system and act by disrupting microbial membranes and/or targeting intracellular processes. LL-37 is the primary human AMP. See antimicrobial peptides and innate immunity.

Cell-Penetrating Peptide (CPP)

Short peptides (typically 5–30 amino acids) with the ability to cross cell membranes and transport cargo molecules (drugs, nucleic acids, peptides) into cells. CPPs are typically cationic (rich in arginine and lysine) and can enter cells through direct translocation, endocytosis, or transient pore formation. TAT peptide (from HIV) and penetratin are well-known examples. See cell-penetrating peptides research.

GHRH Analog

A synthetic peptide that mimics the action of growth hormone-releasing hormone (GHRH) at the GHRH receptor on pituitary somatotrophs. GHRH analogs stimulate both GH synthesis and GH secretion, amplifying the natural GH pulsatile pattern. Examples include CJC-1295 (modified GRF 1-29), tesamorelin, and sermorelin. See GH secretagogues complete guide.

GHRP (Growth Hormone-Releasing Peptide)

A class of synthetic peptides that stimulate GH release by activating the GHS-R1a receptor (the ghrelin receptor). GHRPs include GHRP-2, GHRP-6, hexarelin, and ipamorelin. Unlike GHRH analogs, GHRPs primarily amplify the amplitude of GH pulses rather than initiating new pulses. The combination of a GHRH analog and a GHRP produces synergistic GH release.

GLP-1 Agonist

A peptide or small molecule that activates the GLP-1 receptor, mimicking the effects of endogenous glucagon-like peptide-1. GLP-1 agonists enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, promote satiety, and may have cardioprotective and neuroprotective effects. Examples include semaglutide, tirzepatide (dual agonist), and retatrutide (triple agonist). See GLP-1 agonist research guide.

Incretin

A gut hormone released in response to nutrient ingestion that enhances glucose-dependent insulin secretion from pancreatic beta cells. The two main incretins are GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Incretin-based therapies include GLP-1 receptor agonists and DPP-4 inhibitors. Tirzepatide is a dual GLP-1/GIP agonist, and retatrutide adds glucagon receptor agonism. See incretin system science.

Melanocortin

A family of peptide hormones derived from the proopiomelanocortin (POMC) precursor protein, including alpha-MSH, beta-MSH, gamma-MSH, and ACTH. Melanocortins act at the five melanocortin receptors (MC1R–MC5R) and regulate pigmentation, inflammation, energy homeostasis, and sexual function. Melanotan II is a synthetic melanocortin analog. See melanocortin receptor system.

Mitochondrial-Derived Peptide (MDP)

A class of bioactive peptides encoded within the mitochondrial genome (mtDNA). MDPs include humanin (neuroprotective), MOTS-C (metabolic regulator), and SHLPs (small humanin-like peptides). MDPs act as retrograde signals from mitochondria to the nucleus and other organelles, coordinating cellular stress responses and metabolic adaptation. See mitochondrial peptides guide.

Neuropeptide

A peptide produced and released by neurons that acts as a neurotransmitter or neuromodulator in the nervous system. Neuropeptides include endorphins, enkephalins, substance P, neuropeptide Y, oxytocin, vasopressin, and many others. They typically modulate rather than mediate fast synaptic transmission, producing slower, longer-lasting effects on neural circuits. See neuropeptide signaling in the brain.

Peptidomimetic

A synthetic molecule designed to mimic the three-dimensional structure and biological activity of a peptide while incorporating modifications that improve drug-like properties (metabolic stability, oral bioavailability, membrane permeability). Peptidomimetics may contain non-natural amino acids, modified peptide bonds, or entirely non-peptide scaffolds that reproduce key pharmacophoric features.

Vasoactive Peptide

A peptide that affects blood vessel tone and blood pressure. Vasoactive peptides include vasoconstrictors (angiotensin II, endothelin) and vasodilators (bradykinin, ANP, VIP). BPC-157 has vasoactive properties through its interaction with the NO system, promoting angiogenesis and normalizing blood pressure. See peptides for heart health.

Practical Research Terms

Aliquot

A precisely measured portion of a solution, prepared by dividing a larger volume into smaller equal parts. In peptide research, reconstituted peptide solutions are often aliquoted into individual-use portions to avoid repeated freeze-thaw cycles that can degrade the peptide. Aliquots are stored frozen and thawed only when needed.

Bacteriostatic Water (BAC Water)

Sterile water containing 0.9% benzyl alcohol as a preservative, used for reconstituting lyophilized peptides. The benzyl alcohol inhibits bacterial growth, allowing multi-use vials. Bacteriostatic water is the standard reconstitution solvent for most research peptides. It should meet USP standards and be used within 28 days of first puncture. See bacteriostatic water and peptide mixing guide.

Cold Chain

An unbroken series of temperature-controlled storage and distribution activities that maintains a product within a specified temperature range from manufacture to end use. Most peptides require cold chain management: lyophilized peptides are stored at 2–8°C (refrigerated) or -20°C (frozen), while reconstituted solutions should be refrigerated and used within weeks. See peptide travel and storage guide.

Dead Volume

The volume of liquid that remains in a syringe, needle hub, or vial after a dose has been drawn or administered. Dead volume represents wasted peptide and must be accounted for in dosing calculations. Low dead-volume syringes can reduce waste by 50–90% compared to standard syringes. See insulin syringe and peptide dosing guide.

Insulin Unit (IU) on Syringes

The measurement markings on insulin syringes, which are calibrated for insulin at U-100 concentration (100 units per mL). Since 100 IU = 1 mL, each IU mark on an insulin syringe represents 0.01 mL (10 microliters). Peptide researchers use insulin syringes for their fine graduations and low dead volume, but must convert desired volume (based on peptide concentration) to IU markings. See insulin syringe guide and peptide dosage calculator.

Intramuscular (IM)

A route of injection delivering a substance into the body of a skeletal muscle. IM injection provides a depot effect with somewhat slower absorption than subcutaneous injection for most peptides. It is less commonly used for peptides than subcutaneous injection but may be preferred for certain preparations. See SC vs. IM peptide injection comparison.

Intranasal (IN)

A route of administration delivering a substance through the nasal mucosa. Intranasal delivery can achieve direct nose-to-brain transport via olfactory and trigeminal nerve pathways, bypassing the BBB. This route is used for CNS-targeted peptides like Semax and Selank. See nasal spray vs. injection guide and nasal spray preparation guide.

Loading Dose

An initial higher dose of a drug administered to rapidly achieve therapeutic plasma concentrations before transitioning to a lower maintenance dose. Loading doses are calculated based on the volume of distribution and target concentration. Some GLP-1 agonist protocols use loading (titration) strategies to manage gastrointestinal side effects. See GLP-1 dose escalation guide.

Lyophilized Cake

The dry, porous solid that remains after lyophilization (freeze-drying) of a peptide solution. A well-formed cake appears as a white to off-white fluffy solid that occupies the same volume as the original frozen solution. Collapsed or discolored cakes may indicate degradation during the lyophilization process or improper storage. See peptide degradation signs.

Reconstitution

The process of dissolving a lyophilized peptide powder in a suitable solvent (typically bacteriostatic water or sterile water) to create an injectable solution. Proper reconstitution technique involves gently directing the solvent down the vial wall onto the powder and allowing dissolution without excessive agitation, which can damage the peptide through shear stress and foaming. See peptide reconstitution complete guide and advanced reconstitution techniques.

Subcutaneous (SC/SubQ)

A route of injection delivering a substance into the fatty tissue layer between the skin and the underlying muscle. Subcutaneous injection is the most common administration route for research peptides. It provides predictable absorption kinetics, is relatively easy to perform, and creates a local depot from which the peptide is gradually absorbed into systemic circulation. See subcutaneous injection technique guide.

Titration

The process of gradually adjusting a drug dose upward (up-titration) or downward (down-titration) to find the optimal dose that maximizes efficacy while minimizing side effects. Titration is particularly important for GLP-1 agonists (to manage GI effects), GH secretagogues (to optimize GH response), and any peptide with a narrow therapeutic window. See peptide dose titration protocol.

Endocrine and Metabolic Terms

AMPK (AMP-Activated Protein Kinase)

A master cellular energy sensor activated when the AMP/ATP ratio increases (indicating energy deficit). AMPK activation stimulates catabolic pathways (glucose uptake, fatty acid oxidation, autophagy) and inhibits anabolic pathways (protein synthesis, lipogenesis). MOTS-C is a potent AMPK activator, and SLU-PP-332 activates related metabolic pathways. See MOTS-C metabolism research.

Autocrine

A mode of cell signaling in which a cell secretes a signaling molecule that acts on receptors on the same cell. Many peptide growth factors (including BDNF in neurons) act in an autocrine manner, creating positive feedback loops that amplify local signaling.

BDNF (Brain-Derived Neurotrophic Factor)

A neurotrophin protein that promotes neuronal survival, dendritic growth, synaptic plasticity, and adult hippocampal neurogenesis through activation of TrkB receptors. BDNF is critical for learning, memory, and cognitive function. Semax is a potent upregulator of BDNF expression. BDNF levels decline with aging and are reduced in depression and neurodegenerative diseases. See nootropic peptides guide.

Endocrine

A mode of cell signaling in which hormones are secreted into the bloodstream and act on distant target organs. Classical endocrine peptide hormones include insulin, glucagon, GH, ACTH, and GLP-1. Many research peptides mimic endocrine signaling molecules. See peptide hormones and the endocrine system.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

An incretin hormone released from K cells of the upper small intestine in response to nutrient ingestion. GIP enhances glucose-dependent insulin secretion and has complex effects on fat metabolism. Tirzepatide is a dual GLP-1/GIP receptor agonist, and retatrutide includes GIP receptor agonism among its triple mechanism. See incretin system science.

HGF (Hepatocyte Growth Factor)

A pleiotropic growth factor that activates the c-Met receptor tyrosine kinase. In the brain, HGF/c-Met signaling promotes synaptogenesis, dendritic spine formation, and memory consolidation. The peptide Dihexa acts as an allosteric potentiator of HGF/c-Met signaling at picomolar concentrations. See Dihexa cognitive peptide research.

IGF-1 (Insulin-Like Growth Factor 1)

A peptide hormone produced primarily by the liver in response to growth hormone stimulation. IGF-1 mediates many of GH’s anabolic effects including protein synthesis, cell proliferation, and tissue growth. In the brain, IGF-1 promotes neuronal survival, synaptic plasticity, and neurogenesis. GH secretagogues like CJC-1295 and ipamorelin increase endogenous IGF-1 levels. See IGF-1 and GH secretagogues guide.

mTOR (Mechanistic Target of Rapamycin)

A serine/threonine protein kinase that integrates signals from growth factors, nutrients, and cellular energy status to regulate cell growth, proliferation, and protein synthesis. mTOR signaling is activated by IGF-1 and amino acids and is relevant to the anabolic effects of GH secretagogues and the muscle-building properties of various peptides. See peptides for lean muscle gain.

Neurogenesis

The formation of new neurons from neural stem cells. In adults, neurogenesis primarily occurs in the hippocampal dentate gyrus (subgranular zone) and the subventricular zone of the lateral ventricles. Adult hippocampal neurogenesis is promoted by exercise, BDNF, serotonin, IGF-1, and several research peptides. Neurogenesis contributes to learning, memory, and cognitive flexibility. See peptides for cognitive decline.

NGF (Nerve Growth Factor)

A neurotrophin that primarily supports the survival, development, and maintenance of cholinergic neurons in the basal forebrain. NGF signals through the TrkA receptor and is critical for attention and memory encoding systems. NGF decline is implicated in Alzheimer’s disease pathology. Semax and GHK-Cu upregulate NGF expression.

Paracrine

A mode of cell signaling in which a cell secretes a signaling molecule that acts on nearby cells (but not on the secreting cell itself). Many peptide growth factors act in a paracrine manner, creating local signaling gradients that guide tissue repair, inflammation, and development. BPC-157 appears to influence paracrine growth factor signaling.

Somatopause

The age-related decline in growth hormone secretion and circulating IGF-1 levels that begins around age 30 and accelerates after age 50. Somatopause is associated with decreased muscle mass, increased adiposity, reduced bone density, impaired cognitive function, and accelerated aging. GH secretagogues aim to partially reverse somatopause effects. See GH secretagogues guide.

Telomerase

A ribonucleoprotein enzyme that adds TTAGGG repeat sequences to the ends of telomeres, counteracting the telomere shortening that occurs with each cell division. Most somatic cells have low or absent telomerase activity, limiting their replicative capacity. Epithalon activates telomerase expression, potentially extending the replicative lifespan of stem cells and other dividing cells. See Epithalon telomere research.

Telomere

Repetitive DNA sequences (TTAGGG in humans) and associated proteins that cap the ends of chromosomes, protecting them from degradation, fusion, and recognition as DNA damage. Telomeres shorten with each cell division, and critically short telomeres trigger cellular senescence or apoptosis. Telomere length is considered a biomarker of biological aging.

Immunology and Inflammation Terms

Anti-Inflammatory Peptide

A peptide that reduces inflammatory responses through one or more mechanisms: suppressing pro-inflammatory cytokine production, promoting anti-inflammatory cytokine release, modulating immune cell activation, or resolving established inflammation. Key anti-inflammatory research peptides include BPC-157, KPV, and TB-500. See peptides for inflammation research.

Cytokine

A broad category of small signaling proteins released by cells that have specific effects on cell-to-cell communication and immune function. Pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) promote inflammation, while anti-inflammatory cytokines (IL-10, IL-4, TGF-beta) resolve it. Many research peptides modulate cytokine profiles. See immune system peptides guide.

Immunomodulation

The modification of immune system activity — either enhancement (immunostimulation) or suppression (immunosuppression) — by a therapeutic agent. Immunomodulatory peptides like Thymosin alpha-1 and Selank adjust immune function toward homeostasis rather than simply suppressing or stimulating it. See Thymosin alpha-1 guide.

NF-kB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)

A transcription factor complex that is a master regulator of inflammatory gene expression. NF-kB activation induces the production of pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes. Many anti-inflammatory peptides, including KPV, exert their effects partly through NF-kB inhibition. See KPV anti-inflammatory peptide guide.

Thymosin

A family of peptides originally isolated from the thymus gland. Thymosin alpha-1 is an immunomodulatory peptide used clinically for hepatitis B/C and as an immune adjuvant. Thymosin beta-4 (TB-500) promotes tissue repair, reduces inflammation, and supports wound healing through distinct mechanisms. See Thymosin alpha-1 vs. TB-500 comparison.

Tissue Repair and Regeneration Terms

Angiogenesis

The formation of new blood vessels from pre-existing vasculature. Angiogenesis is essential for wound healing, tissue repair, and recovery from ischemic injury. BPC-157 is a potent promoter of angiogenesis, which contributes to its healing effects in tendons, ligaments, muscles, and other tissues. See peptides for tendon and ligament repair.

Collagen Synthesis

The production of collagen, the most abundant protein in the body, by fibroblasts and other cells. Collagen provides structural integrity to skin, tendons, ligaments, bones, and blood vessels. GHK-Cu stimulates collagen synthesis and is used in skin rejuvenation research. See skin rejuvenation peptides guide.

Fibroblast

The most common cell type in connective tissue, responsible for producing the extracellular matrix (collagen, fibronectin, proteoglycans) and for wound repair. Fibroblast activation and migration are key processes in tissue healing and are modulated by several research peptides including BPC-157, TB-500, and GHK-Cu.

Senescence

A state of irreversible cell cycle arrest in which cells remain metabolically active but no longer divide. Senescent cells accumulate with aging and secrete pro-inflammatory factors (the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue. FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent cells. See FOXO4-DRI senolytic research.

Senolytic

An agent that selectively induces death (apoptosis) in senescent cells while sparing healthy cells. Senolytic peptides like FOXO4-DRI work by disrupting the anti-apoptotic mechanisms that allow senescent cells to resist programmed cell death. Clearing senescent cells has been shown to rejuvenate tissues and improve healthspan in animal models. See anti-aging peptides guide.

Regulatory and Industry Terms

503A Pharmacy

A compounding pharmacy that operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, preparing customized medications based on individual patient prescriptions. 503A pharmacies are regulated primarily by state boards of pharmacy. See 503A vs. 503B pharmacy comparison.

503B Outsourcing Facility

A compounding facility that operates under Section 503B of the FD&C Act, allowed to produce larger batches of compounded medications without individual prescriptions but subject to FDA inspection and cGMP requirements. 503B facilities have been major sources of compounded peptides including semaglutide and tirzepatide. See FDA compounding regulations guide.

Bulk Drug Substance (BDS)

An active pharmaceutical ingredient (API) that is allowed to be used by compounding pharmacies for preparing customized medications. The FDA maintains a list of approved bulk drug substances for compounding. Changes to this list directly affect peptide availability through compounding pharmacies. See FDA bulk drug substance list for peptides.

Compounding

The practice of creating customized medications by combining, mixing, or altering ingredients to meet specific patient needs. Peptide compounding includes reconstituting lyophilized peptides, creating custom formulations, and preparing peptide combinations not available as commercial products. See compounded vs. brand tirzepatide.

DEA Scheduling

The classification of drugs by the U.S. Drug Enforcement Administration into five schedules (I–V) based on their medical utility and potential for abuse. Most peptides are not scheduled substances, though some may fall under analog act provisions. See DEA peptide scheduling explained.

For Research Use Only (RUO)

A designation indicating that a product is intended exclusively for laboratory research and is not approved for human or veterinary use. Most research peptides are sold under RUO designation. This designation does not imply any specific quality standard but does exclude the product from FDA-regulated therapeutic use.

Research-Grade Peptide

A peptide manufactured and tested to standards suitable for laboratory research but not meeting full pharmaceutical GMP requirements. Research-grade peptides typically have HPLC purity of 95%+ with COA documentation. They are distinct from pharmaceutical-grade (GMP) peptides, which require additional validation, documentation, and facility standards. See research-grade vs. pharmaceutical peptides.

Analytical Chemistry Terms

Amino Acid Analysis (AAA)

An analytical technique that determines the amino acid composition of a peptide by hydrolyzing peptide bonds and quantifying the individual amino acids. AAA confirms that the correct amino acids are present in the expected ratios and is used to determine net peptide content. It does not provide sequence information (the order of amino acids).

Counterion

An ion that associates with the peptide to maintain electrical neutrality in the solid form. Common counterions in lyophilized peptides include trifluoroacetate (TFA, from HPLC purification) and acetate (from ion exchange). The counterion contributes to the total powder weight but is not biologically active, which is why net peptide content is always less than 100%.

Edman Degradation

A classical method for determining peptide amino acid sequence by sequentially removing and identifying one amino acid at a time from the N-terminus. While largely replaced by mass spectrometry for sequencing, Edman degradation remains useful for confirming the N-terminal sequence of synthetic peptides and verifying the absence of deletion sequences.

Mass Accuracy

The closeness of a measured molecular weight (from mass spectrometry) to the theoretical molecular weight calculated from the amino acid sequence. High mass accuracy (typically less than 5 ppm deviation for high-resolution instruments) provides confident identification of the peptide and detection of modifications, deletions, or impurities.

Retention Time

In HPLC, the time elapsed between sample injection and the emergence (elution) of a compound from the column. Retention time is characteristic of each compound under specific chromatographic conditions and is used for identification. Changes in retention time can indicate peptide modifications or degradation products.

Emerging and Advanced Terms

ADC (Antibody-Drug Conjugate)

A targeted therapy combining an antibody (for specificity) with a cytotoxic drug (for cell killing), connected by a chemical linker. Peptide-drug conjugates (PDCs) apply the same principle using targeting peptides instead of antibodies, offering advantages in tissue penetration and manufacturing simplicity.

Autophagy

A cellular recycling process in which damaged organelles, misfolded proteins, and other cellular debris are enclosed in double-membrane vesicles (autophagosomes) and delivered to lysosomes for degradation. Autophagy declines with aging and is activated by AMPK (stimulated by MOTS-C) and inhibited by mTOR. Enhanced autophagy is associated with longevity and neuroprotection. See anti-aging peptides guide.

Bispecific Peptide

A single peptide molecule designed to bind two different targets simultaneously. Tirzepatide (GLP-1R + GIPR agonist) and retatrutide (GLP-1R + GIPR + GCGR agonist) are examples of multi-receptor agonist peptides. See semaglutide vs. tirzepatide vs. retatrutide comparison.

Blood-Brain Barrier (BBB)

A selective permeability barrier formed by tight junctions between brain capillary endothelial cells that restricts the passage of most molecules from blood to brain. The BBB is a major challenge for CNS-targeted peptide delivery, as most peptides are too large and hydrophilic to cross it passively. Strategies for BBB penetration include intranasal delivery, receptor-mediated transcytosis, and lipophilic modifications. See blood-brain barrier peptide delivery.

Epigenetics

Heritable changes in gene expression that do not involve alterations to the DNA sequence itself. Epigenetic mechanisms include DNA methylation, histone modification, and non-coding RNA regulation. Several peptides, including GHK-Cu, exert their effects partly through epigenetic reprogramming of gene expression patterns. See copper peptides research.

Exercise Mimetic

A compound that replicates some of the molecular and physiological effects of physical exercise without actual physical activity. SLU-PP-332 activates ERR (estrogen-related receptor) transcription factors, mimicking exercise-induced gene expression changes that improve endurance and metabolic health. See SLU-PP-332 exercise mimetic research.

Gut-Brain Axis

The bidirectional communication network between the gastrointestinal tract and the central nervous system, mediated by neural (vagus nerve), hormonal (gut peptides), immune (cytokines), and microbial (metabolites) pathways. Many peptides affect both gut and brain function: GLP-1 agonists influence appetite through the gut-brain axis, and BPC-157 has been shown to affect brain function despite being a gut-derived peptide. See gut-brain axis and peptides.

Peptide Library

A collection of peptides with systematically varied sequences used for screening biological activity. Peptide libraries can be synthesized chemically (combinatorial libraries) or displayed on phage, bacteria, or ribosomes (biological display libraries). Library screening is used to discover new bioactive peptides and optimize existing sequences. See peptide library screening research.

Prodrug

A pharmacologically inactive compound that is converted to the active drug form within the body through enzymatic or chemical processes. Peptide prodrug strategies involve masking the peptide with protecting groups or conjugating it to carriers that are cleaved in vivo, improving oral bioavailability, targeting specific tissues, or extending duration of action. See peptide prodrug strategies.

Proteolysis

The hydrolysis (cleavage) of peptide bonds by proteolytic enzymes (proteases/peptidases). Proteolysis is the primary mechanism of peptide metabolism and the main barrier to peptide oral bioavailability. Strategies to resist proteolysis include D-amino acid substitution, backbone modification, cyclization, PEGylation, and stapling. See peptide degradation pathways.

Proteomics

The large-scale study of proteins and peptides in a biological system, including their expression levels, post-translational modifications, interactions, and functions. Proteomic technologies including mass spectrometry-based methods are used to identify novel bioactive peptides, characterize peptide-protein interactions, and monitor the molecular effects of peptide treatments.

Receptor Occupancy

The fraction of available receptors that are bound by a ligand at any given time. Receptor occupancy determines the magnitude of the biological response and is related to drug concentration through the Kd. Understanding receptor occupancy helps optimize peptide dosing: for most agonists, 50–80% occupancy provides near-maximal response, while higher occupancy may trigger excessive desensitization.

Structure-Activity Relationship (SAR)

The relationship between the chemical structure of a peptide (amino acid sequence, modifications, conformation) and its biological activity. SAR studies systematically modify peptide structure to identify which features are essential for activity (pharmacophore), optimize potency, and improve drug-like properties. See peptide structure-activity relationships.

Ubiquitin-Proteasome System (UPS)

The primary intracellular protein degradation pathway, in which proteins are tagged with ubiquitin chains and degraded by the 26S proteasome. The UPS is essential for protein quality control, cell cycle regulation, and immune function. UPS dysfunction contributes to neurodegenerative diseases. GHK-Cu upregulates UPS components. See peptides for cognitive decline.

Abbreviations Quick Reference

How to Use This Glossary

This peptide glossary is designed to be a living reference that grows alongside the field. Whether you are reading a certificate of analysis for the first time (see our COA reading guide), designing a research protocol (see our stacking protocols guide), or interpreting a published study, this glossary provides the terminology foundation you need.

For researchers new to peptide science, we recommend starting with our peptide research for beginners guide, which provides context for many of these terms in a structured learning format. For those ready to begin hands-on work, our reconstitution guide and bacteriostatic water mixing guide cover the practical skills needed to prepare peptides for research.

Explore our complete catalog of research-grade peptides and visit our research hub for over 350 evidence-based articles covering every aspect of peptide science.